Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Spine | 254.9 | 253.6 | 247.8 | 247.3 | 229.2 | 71.9 | 38.9 | 39.7 |
| Sports Medicine | | | | | | 42.6 | 51.2 | 48.1 |
| Other | 26.0 | 26.0 | 25.1 | 35.0 | 33.7 | 83.5 | 88.1 | 81.5 |
| Total revenues [+] | 280.9 | 279.6 | 272.9 | 282.3 | 262.8 | 198.0 | 178.1 | 169.3 |
| Other | | | | | | 8.2 | 6.4 | 6.5 |
| Revenue growth [+] | 0.5% | 2.5% | -3.3% | 7.4% | 32.7% | 11.2% | 5.2% | 1.9% |
| Spine | 0.5% | 2.4% | 0.2% | 7.9% | 218.9% | 84.9% | -2.2% | 17.2% |
| Sports Medicine | | | | | | -16.8% | 6.4% | 6.8% |
| Cost of goods sold | 140.7 | 137.0 | 140.5 | 132.6 | 129.0 | 117.9 | 92.9 | 92.1 |
| Gross profit | 140.1 | 142.5 | 132.3 | 149.7 | 133.8 | 80.1 | 85.2 | 77.2 |
| Gross margin | 49.9% | 51.0% | 48.5% | 53.0% | 50.9% | 40.5% | 47.8% | 45.6% |
| Selling, general and administrative | 142.6 | 113.7 | 148.0 | 125.1 | 107.7 | 81.6 | 58.4 | 65.4 |
| Research and development | | | | | 15.5 | 15.2 | 12.2 | |
| Other operating expenses | 6.2 | 6.2 | 3.6 | 2.8 | 5.0 | 3.0 | 2.4 | 0.3 |
| EBITDA [+] | 5.9 | 36.9 | -2.7 | 38.3 | 21.0 | -7.6 | 20.2 | 19.5 |
| EBITDA growth | -84.0% | -1450.9% | -107.1% | 82.3% | -377.7% | -137.4% | 4.0% | 31.2% |
| EBITDA margin | 2.1% | 13.2% | -1.0% | 13.6% | 8.0% | -3.8% | 11.4% | 11.5% |
| Depreciation | 10.6 | 10.5 | 12.8 | 12.2 | 11.0 | 8.3 | 6.0 | 6.0 |
| EBITA | -4.7 | 26.4 | -15.6 | 26.1 | 10.0 | -15.8 | 14.3 | 13.4 |
| EBITA margin | -1.7% | 9.4% | -5.7% | 9.2% | 3.8% | -8.0% | 8.0% | 7.9% |
| Amortization of intangibles | 4.0 | 3.7 | 3.7 | 4.3 | 4.4 | 3.9 | 2.0 | 2.0 |
| EBIT [+] | -8.7 | 22.6 | -19.2 | 21.8 | 5.6 | -19.8 | 12.2 | 11.4 |
| EBIT growth | -138.3% | -217.7% | -188.2% | 287.6% | -128.5% | -261.5% | 7.0% | 55.9% |
| EBIT margin | -3.1% | 8.1% | -7.1% | 7.7% | 2.1% | -10.0% | 6.9% | 6.8% |
| Non-recurring items [+] | | | | | | 8.9 | | |
| Legal settlement | | | | | -0.2 | -3.0 | -2.4 | |
| Interest expense, net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.5 | -0.2 | -0.2 |
| Interest expense | 2.8 | 3.2 | 1.7 | 1.5 | 1.4 | 0.5 | | 0.2 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 |
| Other income (expense), net [+] | 5.8 | 6.3 | 3.4 | 2.9 | -0.1 | 0.3 | 0.0 | 0.2 |
| Gain (loss) on sale of assets | | | | | | | 0.0 | |
| Litigation settlement | | | | | 0.2 | 3.0 | 2.4 | |
| Gain (loss) on foreign currency transactions | | | | | -0.1 | 0.3 | 0.0 | |
| Pre-tax income | -5.6 | 25.7 | -17.5 | 23.2 | 4.2 | -28.9 | 12.4 | 11.6 |
| Income taxes | -4.3 | 19.5 | -3.1 | 8.3 | 1.5 | -11.1 | 4.0 | 3.2 |
| Tax rate | 77.6% | 75.6% | 17.5% | 35.7% | 35.6% | 38.4% | 32.5% | 27.8% |
| Net income | -1.3 | 6.3 | -14.4 | 0.0 | -0.4 | -19.2 | 8.4 | 0.0 |
| Net margin | -0.4% | 2.2% | -5.3% | 0.0% | -0.2% | -9.7% | 4.7% | 0.0% |
| |
| Basic EPS [+] | ($0.02) | $0.11 | ($0.25) | $0.00 | ($0.01) | ($0.34) | $0.15 | $0.00 |
| Growth | -118.7% | -142.5% | | -100.0% | -97.8% | -326.8% | | -100.0% |
| Diluted EPS [+] | ($0.02) | $0.10 | ($0.25) | $0.00 | ($0.01) | ($0.34) | $0.15 | $0.00 |
| Growth | -119.0% | -141.9% | | -100.0% | -97.8% | -327.6% | | -100.0% |
| |
| Shares outstanding (basic) [+] | 63.5 | 59.7 | 58.2 | 57.6 | 56.7 | 56.3 | 55.9 | 55.2 |
| Growth | 6.4% | 2.5% | 1.1% | 1.5% | 0.8% | 0.7% | 1.3% | 0.8% |
| Shares outstanding (diluted) [+] | 63.5 | 60.6 | 58.2 | 58.6 | 56.7 | 56.3 | 56.1 | 55.4 |
| Growth | 4.8% | 4.1% | -0.6% | 3.3% | 0.8% | 0.3% | 1.3% | 1.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|